Bio Green Med Solution Inc. (BGMS) Options Positioning, Max Pain & Unusual Sweeps

The Roarable RQD rating is 36 out of 100, graded D-, with the verdict "Roarable Sell — Vulnerable Balance Sheet & Flow" (per the Roarable RQD rating). The score is built from five pillars, each weighted out of 20:

• Fundamental cash engine: 4 / 20. Per the Roarable RQD rating, this pillar reflects ROIC of -35% and an FCF yield of 0%. For a prospective investor, this is the weakest pillar: the business is not currently generating returns on invested capital or free cash flow that would support the equity valuation.
• Whale / 13F flow: 7 / 20. The rating covers institutional accumulation and options positioning. The holders section contains no institutional data, so the score cannot be traced to specific filings in this dossier. Investors should treat this pillar as weakly supported.
• Insider conviction: 5 / 20. Per the Roarable RQD rating, this reflects SEC Form 4 and Congressional PTR cluster flow. No insider transaction detail is provided in the source data, so the reasoning behind the score is not verifiable here.
• Macro regime fit: 10 / 20. Per the Roarable RQD rating, beta is 1.0 with sector sensitivity noted. A beta of 1.0 implies market-level volatility, but the score is held down by the company's weak fundamentals rather than by beta alone.
• Forensic balance sheet: 10 / 20. Per the Roarable RQD rating, Altman Z is 2.5, Piotroski F is 2/9, and Debt/Equity is 0.5. These sit in a middle-to-weak range and indicate balance sheet vulnerability rather than a crisis-level condition.

Taken together, the score points to a stock where the upside case depends on a reversal in cash generation that the reported figures do not yet show. A prospective investor should weigh the very small market capitalization and the sharp recent price decline (-9.79%) against the absence of profitability. Valuation multiples such as P/E cannot be assessed because the source data does not provide them.

Bio Green Med Solution Inc. is a NASDAQ-listed company in the Health Care sector, operating within the Biotechnology: Pharmaceutical Preparations industry (per the company profile). The source data does not describe its products, customers, or revenue model. Reported revenue is $0.0M in each listed fiscal year (per the SEC financials), so the company's current income-generating activity cannot be characterized from the provided material.

Per the SEC financials, the company reported zero revenue and operating losses across all three periods, with negative free cash flow in each. Gross, operating, and net margins are each 0% (per the market data), and ROIC is -35%. The FY 2023 net income figure of $22.6M sits against an operating loss of $-25.5M, which the source data does not explain. The Altman Z-Score of 2.5 and Piotroski F-Score of 2/9 (per the Roarable RQD rating) suggest a weak balance sheet, and Debt/Equity is 0.5. Debt values are listed as N/A for every period, so the leverage figure cannot be reconciled with the period-level data.

• Share sale plan (YELLOW, MARKET WIRE): A GuruFocus item headlined that BGMS stockholders plan to sell 1.1 million shares, with the headline noting the company is not participating in the sale.
• Health care movers (YELLOW, MARKET WIRE): A Benzinga item lists BGMS among health care stocks moving in an after-market session.
• Dilution risk (YELLOW, MARKET WIRE): An ad-hoc-news.de item headlined that the stock faces dilution from a "Future NRG" deal.
• High dividend yield list (YELLOW, MARKET WIRE): A TradingKey item appears in a list of high dividend yield stocks; the company's dividend yield is 0% per the market data, so this item does not reflect a payout.
• Q3 2024 earnings (RED, RISK WATCH): A headline references a narrower-than-expected loss per share but a stock decline. The item's source attribution is unreliable (it is labeled with a non-news domain), and the EPS figure is not provided.
• Unrelated index item (YELLOW, MARKET WIRE): A siam.in item concerns V-Guard Industries (VGUARD.NS), an unrelated Indian listing, and carries no BGMS-specific information.

The Butterfly Supply-Chain Graph lists no supply chain and no proprietary signals (per the Butterfly Supply-Chain Graph).

• What products or services generate the company's revenue, given reported revenue of $0.0M across all periods?
• What explains the FY 2023 net income of $22.6M against an operating loss of $-25.5M?
• What are the terms and size of the "Future NRG" transaction referenced as a dilution risk?
• What is the cash runway, given FY 2025 cash of $3.5M against FCF of $-4.8M?
• What is the debt position, since debt is listed as N/A and Debt/Equity is 0.5?